MX2023003828A - Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2). - Google Patents
Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2).Info
- Publication number
- MX2023003828A MX2023003828A MX2023003828A MX2023003828A MX2023003828A MX 2023003828 A MX2023003828 A MX 2023003828A MX 2023003828 A MX2023003828 A MX 2023003828A MX 2023003828 A MX2023003828 A MX 2023003828A MX 2023003828 A MX2023003828 A MX 2023003828A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- analogues
- glucagon
- peptide
- administration
- Prior art date
Links
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title abstract 4
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se desvelan posologías para la administración de análogos de péptido de glucagón 2 (GLP-2) y su uso médico, por ejemplo, en el tratamiento y/o prevención de trastornos relacionados con el estómago y el intestino y para mejorar los efectos secundarios de quimioterapia y radioterapia. Se describen posologías para la administración de análogos de péptido de tipo glucagón 2 (GLP-2) para inducir el crecimiento longitudinal de los intestinos, por ejemplo, para el tratamiento de pacientes con síndrome de intestino pequeño (SBS). Se describen también los usos médicos para ajustar el volumen del soporte parenteral (PS) proporcionados a los sujetos que reciben tratamiento con análogos de GLP-2 en respuesta al tratamiento y a los algoritmos para determinar los cambios de volumen PS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709643.9A GB201709643D0 (en) | 2017-06-16 | 2017-06-16 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| GBGB1714203.5A GB201714203D0 (en) | 2017-09-05 | 2017-09-05 | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues |
| GBGB1800873.0A GB201800873D0 (en) | 2018-01-19 | 2018-01-19 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003828A true MX2023003828A (es) | 2023-04-13 |
Family
ID=62748940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015054A MX2019015054A (es) | 2017-06-16 | 2018-06-15 | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2). |
| MX2023003828A MX2023003828A (es) | 2017-06-16 | 2019-12-13 | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015054A MX2019015054A (es) | 2017-06-16 | 2018-06-15 | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2). |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20200000883A1 (es) |
| EP (3) | EP4424362A3 (es) |
| JP (2) | JP7200238B2 (es) |
| KR (2) | KR102754148B1 (es) |
| CN (2) | CN111032072A (es) |
| AU (2) | AU2018285580B2 (es) |
| BR (1) | BR112019026711A2 (es) |
| CA (1) | CA3066523A1 (es) |
| CL (1) | CL2019003660A1 (es) |
| CO (1) | CO2019014028A2 (es) |
| DK (2) | DK3638291T3 (es) |
| ES (2) | ES2989204T3 (es) |
| IL (2) | IL271245B2 (es) |
| MX (2) | MX2019015054A (es) |
| PE (1) | PE20200678A1 (es) |
| SG (1) | SG11201912161SA (es) |
| TW (1) | TWI791539B (es) |
| WO (1) | WO2018229252A1 (es) |
| ZA (2) | ZA201908355B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| AU2020363377A1 (en) | 2019-10-07 | 2022-04-21 | Kallyope, Inc. | GPR119 agonists |
| AU2021228729A1 (en) | 2020-02-28 | 2022-09-22 | Kallyope, Inc. | GPR40 agonists |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| EP4262847A1 (en) | 2020-12-16 | 2023-10-25 | Zealand Pharma A/S | Use of glp-2 analogues in patients with renal insufficiency |
| MX2024002569A (es) | 2021-09-10 | 2024-04-30 | Zealand Pharma As | Proceso para formular composiciones que comprenden analogos de peptido 2 similar a glucagon (glp-2). |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| WO2023132609A1 (ko) * | 2022-01-05 | 2023-07-13 | 주식회사 휴온스랩 | 지속형 지방산-펩타이드 유도체 및 이의 용도 |
| EP4482513A4 (en) * | 2022-02-24 | 2026-02-18 | Entera Bio Ltd | FORMULATIONS COMPRISING AN ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-TYPE PEPTIDE-2 |
| CN120051294A (zh) * | 2022-09-30 | 2025-05-27 | 西兰制药公司 | 胰高血糖素样肽-2（glp-2）类似物及其用于治疗短肠综合征（sbs）的医学用途 |
| KR20250137600A (ko) | 2023-01-27 | 2025-09-18 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩타이드-2(glp-2) 유사체 및 단장증후군(sbs) 치료를 위한 이의 의학적 용도 |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2961045B2 (ja) | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| ATE395359T1 (de) | 1996-03-01 | 2008-05-15 | Novo Nordisk As | Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| DK0906338T3 (da) | 1996-04-12 | 2003-03-03 | Ontario Inc 1149336 | Glukagonlignende peptid-2 analoger |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| ES2239364T3 (es) | 1996-09-09 | 2005-09-16 | Zealand Pharma A/S | Sintesis de peptidos en fase solida. |
| US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| WO1998052600A1 (en) | 1997-05-16 | 1998-11-26 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| WO1999058144A1 (en) | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| EP1970072A1 (en) | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| DK1360202T3 (da) | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| JP2005506956A (ja) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | 長時間作用性ｇｌｐ−１製剤 |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| DE60317822D1 (de) | 2002-10-29 | 2008-01-10 | Alza Corp | Stabilisierte feste polypeptidpartikel |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| HUE043210T2 (hu) | 2003-11-20 | 2019-08-28 | Novo Nordisk As | Injekciós eszközök elõállítására optimális propilénglikol-tartalmú peptidkészítmények |
| EP1727560B1 (en) | 2004-01-27 | 2012-09-12 | Kyowa Hakko Kirin Co., Ltd. | Gastrointestinal proliferative factor and uses thereof |
| WO2005082404A2 (en) | 2004-02-27 | 2005-09-09 | Novo Nordisk A/S | Glp-2 derivatives modified by lipophilic substituents |
| WO2006050244A2 (en) * | 2004-11-01 | 2006-05-11 | Nps Allelix Corp. | Treatment of short bowel syndrome patients with colon-in-continuity |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2006242998B2 (en) * | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| CN101331224A (zh) * | 2005-10-24 | 2008-12-24 | 森托科尔公司 | Glp-2模拟体、多肽、组合物、方法和用途 |
| US20090105341A1 (en) | 2005-12-24 | 2009-04-23 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
| US20090028832A1 (en) | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| BRPI0718566A2 (pt) | 2006-11-08 | 2014-03-11 | Zealand Pharma As | Peptídeo, análogo do mesmo, composição farmacêutica, usos de um análogo de peptídeo, e de uma molécula de ácido nucléico, de um vetor de expressão, ou de uma célula hospedeira, molécula de ácido nucléico, vetor de expressão, célula hospedeira, métodos para produzir o análogo de peptídeo-2 tipo-glucagon (glp-2), e, kit terapêutico. |
| AU2007340369C1 (en) | 2006-12-29 | 2013-05-02 | Ipsen Pharma S.A.S. | GLP-1 pharmaceutical compositions |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| UA104605C2 (uk) | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Аналоги глюкагону |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY |
| CN101824087A (zh) | 2009-03-05 | 2010-09-08 | 连云港恒邦医药科技有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JP2013523620A (ja) | 2010-03-26 | 2013-06-17 | ノヴォ ノルディスク アー／エス | 新規のグルカゴンアナログ |
| EP2571896A4 (en) | 2010-05-17 | 2014-01-08 | Cebix Inc | PEGYLATED C-PEPTIDE |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| CN102212127B (zh) | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
| DK2710031T3 (en) | 2011-05-18 | 2018-01-02 | Mederis Diabetes Llc | IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE |
| AU2012308636B2 (en) * | 2011-09-12 | 2017-08-31 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| MX356958B (es) | 2012-05-03 | 2018-06-20 | Zealand Pharma As | Análogos de péptido-2 tipo glucagón (glp-2). |
| NZ704043A (en) | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| US11813328B2 (en) | 2014-10-23 | 2023-11-14 | Amgen Inc. | Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins |
| BR112017013471A2 (pt) | 2014-12-23 | 2018-02-27 | Camurus Ab | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. |
| UA121874C2 (uk) | 2015-02-17 | 2020-08-10 | Елі Ліллі Енд Компані | Порошкова назальна композиція для лікування гіпоглікемії |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| SI3541366T1 (sl) | 2016-11-21 | 2025-05-30 | Amylyx Pharmaceuticals, Inc. | Zapufrane formulacije eksendina (9-39) |
| JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア／エス | アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| WO2018142363A1 (en) | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| GB201710822D0 (en) | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| US20190275110A1 (en) | 2017-12-07 | 2019-09-12 | Adocia | Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| KR20210126088A (ko) * | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
-
2018
- 2018-06-15 BR BR112019026711-5A patent/BR112019026711A2/pt unknown
- 2018-06-15 DK DK18734135.9T patent/DK3638291T3/da active
- 2018-06-15 ES ES21150552T patent/ES2989204T3/es active Active
- 2018-06-15 EP EP24182737.7A patent/EP4424362A3/en active Pending
- 2018-06-15 WO PCT/EP2018/065951 patent/WO2018229252A1/en not_active Ceased
- 2018-06-15 PE PE2019002548A patent/PE20200678A1/es unknown
- 2018-06-15 KR KR1020237006296A patent/KR102754148B1/ko active Active
- 2018-06-15 EP EP18734135.9A patent/EP3638291B1/en active Active
- 2018-06-15 DK DK21150552.4T patent/DK3881861T3/da active
- 2018-06-15 KR KR1020207001446A patent/KR102504200B1/ko active Active
- 2018-06-15 MX MX2019015054A patent/MX2019015054A/es unknown
- 2018-06-15 SG SG11201912161SA patent/SG11201912161SA/en unknown
- 2018-06-15 CA CA3066523A patent/CA3066523A1/en active Pending
- 2018-06-15 IL IL271245A patent/IL271245B2/en unknown
- 2018-06-15 ES ES18734135T patent/ES2894629T3/es active Active
- 2018-06-15 IL IL299864A patent/IL299864B2/en unknown
- 2018-06-15 AU AU2018285580A patent/AU2018285580B2/en active Active
- 2018-06-15 EP EP21150552.4A patent/EP3881861B1/en active Active
- 2018-06-15 TW TW107120806A patent/TWI791539B/zh active
- 2018-06-15 CN CN201880053014.6A patent/CN111032072A/zh active Pending
- 2018-06-15 CN CN202410762243.2A patent/CN118526577A/zh active Pending
- 2018-06-15 JP JP2020519850A patent/JP7200238B2/ja active Active
-
2019
- 2019-07-15 US US16/511,766 patent/US20200000883A1/en not_active Abandoned
- 2019-12-12 CO CONC2019/0014028A patent/CO2019014028A2/es unknown
- 2019-12-13 CL CL2019003660A patent/CL2019003660A1/es unknown
- 2019-12-13 ZA ZA2019/08355A patent/ZA201908355B/en unknown
- 2019-12-13 MX MX2023003828A patent/MX2023003828A/es unknown
-
2022
- 2022-12-20 JP JP2022203265A patent/JP7566859B2/ja active Active
-
2023
- 2023-10-27 US US18/496,636 patent/US12297251B1/en active Active
-
2024
- 2024-03-13 ZA ZA2024/02068A patent/ZA202402068B/en unknown
- 2024-04-16 AU AU2024202486A patent/AU2024202486B2/en active Active
- 2024-11-22 US US18/956,370 patent/US20250136657A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202402068B (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues | |
| Tarazi et al. | Emerging therapies for Parkinson's disease: from bench to bedside | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| PH12014502058A1 (en) | Pharmaceutical composition comprising empagliflozin and antiobesity drug | |
| PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| HRP20201069T1 (hr) | Primjena tasimelteona pod uvjetima natašte | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12021551805A1 (en) | Treatment of skin lesions and pruritus in prurigo nodularis patients | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| HK1223630A1 (zh) | 抗-egfr疗法的实施与用量 | |
| AR112109A1 (es) | Regímenes de dosificación para la administración de análogos de glucagón-péptido-2 (glp-2) | |
| Eron Jr et al. | Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment‐naïve HIV‐infected individuals | |
| WO2019244014A3 (en) | New use of inhibitors of monoamine oxidase type b | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| Arceci | Dendritic cell disorders: matters of lineage and clinical drug testing in rare diseases | |
| Tereshina et al. | INFLUENCE OF REAMBERIN® AND CYCLOFERON® ON CONCETRATION OF" AVERAGE MOLECULES" IN SERUM OF PATIENTS WITH RECCURENT DEPRESSIVE DISORDERS IN OUTPATIENT OBSERVATION |